The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a letter to healthcare professionals: Esmya (ulipristal acetate) for uterine fibroids: monitor liver function in current and recent users; do not initiate treatment in new users or those between treatment courses. New temporary safety measures have been introduced for Esmya following reports of serious liver injury in women using the medicine for uterine fibroids.
The emergency contraceptive ellaOne also contains ulipristal acetate (single-dose, 30mg). No cases of serious liver injury have been reported with ellaOne and there are no concerns with this medicine at this time.
Further details of the letter and action to take are available on the CAS website.